OKYO Pharma (OKYO Pharma) 3-Year Book Growth Rate : -41.90% (As of Mar. 2023)

View and export this data going back to 2022. Start your Free Trial

What is OKYO Pharma 3-Year Book Growth Rate?

OKYO Pharma's Book Value per Share for the quarter that ended in Mar. 2023 was $-0.04.

During the past 12 months, OKYO Pharma's average Book Value per Share Growth Rate was -128.80% per year. During the past 3 years, the average Book Value per Share Growth Rate was -41.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

During the past 13 years, the highest 3-Year average Book Value per Share Growth Rate of OKYO Pharma was 418.00% per year. The lowest was -77.20% per year. And the median was -9.65% per year.

Competitive Comparison of OKYO Pharma's 3-Year Book Growth Rate

For the Biotechnology subindustry, OKYO Pharma's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

OKYO Pharma's 3-Year Book Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OKYO Pharma's 3-Year Book Growth Rate distribution charts can be found below:

* The bar in red indicates where OKYO Pharma's 3-Year Book Growth Rate falls into.

OKYO Pharma 3-Year Book Growth Rate Calculation

This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

OKYO Pharma (NAS:OKYO) 3-Year Book Growth Rate Explanation

Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.

OKYO Pharma 3-Year Book Growth Rate Related Terms

Thank you for viewing the detailed overview of OKYO Pharma's 3-Year Book Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

OKYO Pharma (OKYO Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OKYO Pharma Ltd (NAS:OKYO) » Definitions » 3-Year Book Growth Rate

Comparable Companies

Traded in Other Exchanges

OK10:Germany

Address

14/15 Conduit St, Floor 4, London, GBR, W1S 2XJ

Website

https://www.okyopharma.com

OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions on various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.

Executives

John P Brancaccio	director	C/O TAMIR BIOTECHNOLOGY, INC., 11 DEER PARK DRIVE, SUITE 204, MONMOUTH JUNCTION NJ 08852
Gary S Jacob	director, officer: Chief Executive Officer
Gabriele M Cerrone	director, 10 percent owner, officer: Executive Chairman	265 EAST 66TH STREET, SUITE 16G, NEW YORK NY 10021
Bernard Denoyer	director	C/O CALLISTO PHARMACEUTICALS, INC., 420 LEXINGTON AVENUE, SUITE 1609, NEW YORK NY 10170
Willy Jules Simon	director	PLAYLOGIC INTERNATIONAL NV, CONCERTGEBOUWPLEIN 13, AMSTERDAM P7 1071 LL
Keeren Shah	officer: Chief Financial Officer	55 PARK LANE, LONDON X0 W1K 1NA